Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TPMT | P51580 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30803084 | 0.83 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10CA12CA1 | |
| SCHEMBL13835746 | 0.83 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10CA12CA1 | |
| SCHEMBL13888143 | 0.82 | TDP1 (0.50) | KDM4EALDH1A1HSD17B10METAP2CA12 | |
| SCHEMBL6357203 | 0.82 | TDP1 (0.46) | DRD2KDM4EALDH1A1HSD17B10METAP2 | |
| SCHEMBL20018063 | 0.81 | ALDH1A1 (0.71) | KDM4EALDH1A1HSD17B10METAP2CA12 | |
| Hydrochloric Acid SCHEMBL9876725 | 0.81 | TDP1 (0.49) | KDM4EALDH1A1HSD17B10METAP2CA12 | |
| SCHEMBL12504376 | 0.79 | TRPV1 (0.43) | DRD2TRPV1POLBCA12CA1 | |
| SCHEMBL28902668 | 0.78 | KDM4E (0.47) | KDM4EALDH1A1HSD17B10POLBCA12 | |
| SCHEMBL31746160 | 0.78 | TDP1 (0.53) | KDM4EALDH1A1HSD17B10POLBCA12 | |
| SCHEMBL2646567 | 0.77 | HSD17B10 (0.46) | KDM4EALDH1A1HSD17B10METAP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107014934-B | Quality control product of urine organic acid filter paper and preparation method thereof | 广州金域医学检验中心有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20090042946-A1 | METHOD AND KIT FOR CONTROLLING BLEEDING | MOORE II BOB M | 2009-02-12 | — | — | US | disclosed |
| EP-1635689-A4 | METHOD AND KIT FOR CONTROLLING BLEEDING | UNIV TENNESSEE RES FOUNDATION (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1635689-A2 | METHOD AND KIT FOR CONTROLLING BLEEDING | University of Tennessee Research Foundation (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004093664-A2 | METHOD AND KIT FOR CONTROLLING BLEEDING | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040202735-A1 | Method and kit for controlling bleeding | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | DRD2 971/4885KDM4E 3617/4885ALDH1A1 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.